Study of F8IL10 injections for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests if a new drug called F8IL10, given as an injection directly into an inflamed joint, can help people with rheumatoid arthritis. It is for adults who have had RA for more than 6 months and still have joint swelling despite their current medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have been diagnosed with rheumatoid arthritis for at least 6 months.
- You currently have a swollen, painful knee, ankle, shoulder, wrist, or elbow that your doctor can inject.
- You are on stable doses of your RA medications for at least 3 months, and steroids (if used) are at 10 mg per day or less.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This is an early-stage study testing a new injectable treatment called KT502 for people with moderate-to-severe rheumatoid arthritis (RA) that hasn't responded well to standard treatments. The study will check if the medication is safe and how the body responds to it.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial tests a new medicine called CLN-978, given as an injection under the skin, to see if it can help people with active rheumatoid arthritis who haven't improved enough with other treatments. CLN-978 works by targeting a specific immune cell to reduce inflammation.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.